Total (n=49) | MMF group (n=20) | CYC group (n=18) | The other-regimens group (n=11) | p Value* | |
Follow-up time, months | 100.17 (51.82–186.20) | 149.88 (97.47–191.53) | 96.35 (25.36–169.06) | 81.60 (34.90–119.90) | 0.114 |
Treatment response | |||||
Complete remission | 22 (44.90) | 13 (65.00) | 3 (16.67) | 6 (54.55) | 0.004 |
Partial remission | 27 (55.10) | 15 (75.00) | 6 (33.33) | 6 (54.55) | 0.021 |
Total remission | 27 (55.10) | 15 (75.00) | 6 (33.33) | 6 (54.55) | 0.021 |
Renal relapse | 8 (29.63) | 5 (33.33) | 2 (33.33) | 1 (16.67) | 0.900 |
Clinical data at the last follow-up | |||||
SLEDAI, score | 2 (0–6) | 2 (0–4) | 4 (2–11) | 2 (0–5) | 0.015 |
Proteinuria, g/24 hours | 0.39 (0.79–1.06) | 0.28 (0.13–0.49) | 1.06 (0.43–3.53) | 0.25 (0.18–0.49) | 0.001 |
Urinary RBC count, ×104/mL | 1 (1–6) | 1 (1–5) | 5 (1–51) | 1 (1–2) | 0.083 |
SAlb, g/L | 41.00 (36.00–44.10) | 43.50 (39.18–45.10) | 35.75 (33.13–42.05) | 43.1 (40.75–45.25) | 0.013 |
SCr, μmol/L | 76.02 (54.80–113.15) | 68.95 (53.26–91.72) | 109.17 (74.92–260.12) | 50.39 (42.43–71.16) | 0.011 |
Adverse events | |||||
Infection | 29 (59.18) | 12 (60.00) | 12 (66.67) | 5 (45.45) | 0.671 |
Arthralgia | 9 (18.37) | 3 (15.00) | 3 (16.67) | 3 (27.27) | 0.900 |
Arthrosis necrosis | 2 (4.08) | 0 (0.00) | 2 (11.11) | 0 (0.00) | 0.218 |
Menstrual disorder or menolipsis | 10 (20.41) | 6 (30.00) | 3 (16.67) | 1 (9.09) | 0.454 |
Cardiac vascular disease | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0.900 |
Tumour | 1 (2.04) | 0 (0.00) | 0 (0.00) | 1 (9.09) | 0.900 |
Epilepsy | 2 (4.08) | 1 (5.00) | 1 (5.56) | 0 (0.00) | 0.900 |
Values are given as n (%) or median (IQR).
*Comparison of MMF with CYC in the treatment of ANCA-positive LN patients.
CYC, cyclophosphamide; MMF, mycophenolate mofetil; RBC, red blood cell; SAlb, serum albumin; SCr, serum creatinine; SLEDAI, systemic lupus erythematosus disease activity index.